Remy Durand - 08 May 2024 Form 4 Insider Report for ALPINE IMMUNE SCIENCES, INC.

Role: Chief Business Officer
Signature: /s/ James Paul Rickey, attorney-in-fact
Issuer symbol: N/A
Transactions as of: 08 May 2024
Net transactions value: +$513,869
Form type: 4
Filing time: 10 May 2024, 19:25:13 UTC
Previous filing: 05 Jan 2024
Next filing: 20 May 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ALPN	Common Stock	Options Exercise	$129,954	+9,845	+26%	$13.20	47,949	08 May 2024	Direct	F1
transaction	ALPN	Common Stock	Options Exercise	$162,750	+25,000	+52%	$6.51	72,949	08 May 2024	Direct
transaction	ALPN	Common Stock	Options Exercise	$50,573	+12,365	+17%	$4.09	85,314	08 May 2024	Direct
transaction	ALPN	Common Stock	Options Exercise	$122,992	+38,078	+45%	$3.23^*	123,392	08 May 2024	Direct
transaction	ALPN	Common Stock	Options Exercise	$47,600	+10,000	+8.1%	$4.76	133,392	08 May 2024	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ALPN	Stock Option (Right to buy)	Options Exercise	$0	-9,845	-12%	$0.000000	70,155	08 May 2024	Common Stock	9,845	$13.20	Direct	F2, F3
transaction	ALPN	Stock Option (Right to buy)	Options Exercise	$0	-25,000	-100%	$0.000000^*	0	08 May 2024	Common Stock	25,000	$6.51	Direct	F2, F4
transaction	ALPN	Stock Option (Right to buy)	Options Exercise	$0	-12,365	-82%	$0.000000	2,635	08 May 2024	Common Stock	12,365	$4.09	Direct	F2, F5
transaction	ALPN	Stock Option (Right to buy)	Options Exercise	$0	-38,078	-59%	$0.000000	26,922	08 May 2024	Common Stock	38,078	$3.23	Direct	F2, F6
transaction	ALPN	Stock Option (Right to buy)	Options Exercise	$0	-10,000	-100%	$0.000000^*	0	08 May 2024	Common Stock	10,000	$4.76	Direct	F2, F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 31,200 shares of common stock underlying a restricted stock unit grant made on January 4, 2024.
F2	The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.
F3	One-fourth (1/4) of the shares subject to the option will vest on January 5, 2022, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to be a service provider through each such date.
F4	One-fourth (1/4) of the shares subject to the option will vest on February 6, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to be a service provider through each such date.
F5	One-fourth (1/4) of the shares subject to the option will vest on May 1, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to be a service provider through each such date.
F6	One-fourth (1/4) of the shares subject to the option will vest on January 23, 2021, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to be a service provider through each such date.
F7	One-fourth (1/4) of the shares subject to the option will vest on October 8, 2019, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to be a service provider through each such date.